Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?
Open Access
- 12 January 2021
- journal article
- Published by Heighten Science Publications Corporation in Annals of Clinical Hypertension
- Vol. 5 (1), 001-002
- https://doi.org/10.29328/journal.ach.1001025
Abstract
Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.Keywords
This publication has 9 references indexed in Scilit:
- Cardiotoxic effects of angiogenesis inhibitorsClinical Science, 2021
- Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and PathophysiologyJournal of Clinical Medicine, 2020
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted TherapyCancers, 2020
- Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)Cancer, 2018
- Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular DiseaseHypertension, 2018
- Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 PatientsClinical Journal of Sport Medicine, 2017
- Proteinuria and hypertension with tyrosine kinase inhibitorsKidney International, 2011
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsClinical Cancer Research, 2011
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI Journal of the National Cancer Institute, 2010